6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
important	JJ	important	important	import	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
below	IN	below	below	below	N	O
and	CC	and	and	and	N	O
elsewhere	RB	elsewhere	elsewhere	elsewher	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Hypotension	NNP	hypotension	hypotension	hypotens	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Impairment	NN	impairment	impairment	impair	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
Renal	NNP	renal	renal	renal	N	I-AdverseReaction
Function	NNP	function	function	function	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Hyperkalemia	NNP	hyperkalemia	hyperkalemia	hyperkalemia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
with	IN	with	with	with	N	O
Concomitant	NNP	concomitant	concomitant	concomit	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
and	CC	and	and	and	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
Secretagogues	NNP	secretagogues	secretagogues	secretagogu	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Genital	NNP	genital	genital	genit	N	B-AdverseReaction
Mycotic	NNP	mycotic	mycotic	mycot	N	I-AdverseReaction
Infections	NNP	infections	infection	infect	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Bone	NNP	bone	bone	bone	N	B-AdverseReaction
Fracture	NNP	fracture	fracture	fractur	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
Low	NNP	low	low	low	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Density	NN	density	density	densiti	N	I-AdverseReaction
Lipoprotein	NNP	lipoprotein	lipoprotein	lipoprotein	N	I-AdverseReaction
(	(	(	(	(	N	O
LDL	NNP	ldl	ldl	ldl	Y	O
-	:	-	-	-	N	O
C	NNP	c	c	c	N	O
)	)	)	)	)	N	O
[	VBD	[	[	[	N	O
see	JJ	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O

Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
incidence	NN	incidence	incidence	incid	N	O
)	)	)	)	)	N	O
:	:	:	:	:	N	O
female	JJ	female	female	femal	N	B-AdverseReaction
genital	JJ	genital	genital	genit	N	I-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
urination	NN	urination	urination	urin	N	I-AdverseReaction
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Janssen	NNP	janssen	janssen	janssen	N	O
Pharmaceuticals	NNP	pharmaceuticals	pharmaceutical	pharmaceut	N	O
,	,	,	,	,	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
526	CD	526	526	526	N	O
-	:	-	-	-	N	O
7736	CD	7736	7736	7736	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O

Studies	NNS	studies	study	studi	N	O
Experience	NNP	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O

The	DT	the	the	the	N	O
data	NN	data	data	data	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
is	VBZ	is	is	is	N	O
derived	VBN	derived	derived	deriv	N	O
from	IN	from	from	from	N	O
four	CD	four	four	four	N	O
26	CD	26	26	26	N	O
-	:	-	-	-	N	O
week	NN	week	week	week	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
one	CD	one	one	one	N	O
trial	NN	trial	trial	trial	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
was	VBD	was	wa	wa	N	O
used	VBN	used	used	use	N	O
as	IN	as	a	as	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
three	CD	three	three	three	N	O
trials	NNS	trials	trial	trial	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
was	VBD	was	wa	wa	N	O
used	VBN	used	used	use	N	O
as	IN	as	a	as	N	O
add	JJ	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
therapy	NN	therapy	therapy	therapi	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
data	NNS	data	data	data	N	O
reflect	VBP	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
of	IN	of	of	of	N	O
1667	CD	1667	1667	1667	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
of	IN	of	of	of	N	O
24	CD	24	24	24	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
833	CD	833	833	833	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
834	CD	834	834	834	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
646	CD	646	646	646	N	O
)	)	)	)	)	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
was	VBD	was	wa	wa	N	O
56	CD	56	56	56	N	O
years	NNS	years	year	year	N	O
and	CC	and	and	and	N	O
2%	CD	2%	2%	2%	N	O
were	VBD	were	were	were	N	O
older	JJR	older	older	older	N	O
than	IN	than	than	than	N	O
75	CD	75	75	75	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
.	.	.	.	.	N	O

Fifty	NNP	fifty	fifty	fifti	N	O
percent	NN	percent	percent	percent	N	O
(	(	(	(	(	N	O
50%	CD	50%	50%	50%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
was	VBD	was	wa	wa	N	O
male	JJ	male	male	male	N	O
and	CC	and	and	and	N	O
72%	CD	72%	72%	72%	N	O
were	VBD	were	were	were	N	O
Caucasian	NNP	caucasian	caucasian	caucasian	N	O
,	,	,	,	,	N	O
12%	CD	12%	12%	12%	N	O
were	VBD	were	were	were	N	O
Asian	JJ	asian	asian	asian	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
5%	CD	5%	5%	5%	N	O
were	VBD	were	were	were	N	O
Black	NNP	black	black	black	N	O
or	CC	or	or	or	N	O
African	JJ	african	african	african	N	O
American	NNP	american	american	american	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
baseline	PDT	baseline	baseline	baselin	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
had	VBD	had	had	had	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
for	IN	for	for	for	N	O
an	DT	an	an	an	N	O
average	NN	average	average	averag	N	O
of	IN	of	of	of	N	O
7.3	CD	7.3	7.3	7.3	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
HbA1C	NNP	hba1c	hba1c	hba1c	Y	O
of	IN	of	of	of	N	O
8.0%	CD	8.0%	8.0%	8.0%	N	O
and	CC	and	and	and	N	O
20%	CD	20%	20%	20%	N	O
had	VBD	had	had	had	N	O
established	VBN	established	established	establish	N	O
microvascular	JJ	microvascular	microvascular	microvascular	N	O
complications	NNS	complications	complication	complic	N	O
of	IN	of	of	of	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
.	.	.	.	.	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
was	VBD	was	wa	wa	N	O
normal	JJ	normal	normal	normal	N	O
or	CC	or	or	or	N	O
mildly	RB	mildly	mildly	mildli	N	O
impaired	JJ	impaired	impaired	impair	N	O
(	(	(	(	(	N	O
mean	JJ	mean	mean	mean	N	O
eGFR	VBP	egfr	egfr	egfr	N	O
88	CD	88	88	88	N	O
mL	NNS	ml	ml	ml	N	O
min	RB	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NNS	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
shows	NNS	shows	show	show	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	O
present	JJ	present	present	present	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
more	JJR	more	more	more	N	O
commonly	RB	commonly	commonly	commonli	N	O
on	IN	on	on	on	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
than	IN	than	than	than	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
either	DT	either	either	either	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
or	CC	or	or	or	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
From	IN	from	from	from	N	O
Pool	NNP	pool	pool	pool	N	O
of	IN	of	of	of	N	O
Four	NNP	four	four	four	N	O
26	CD	26	26	26	N	O
-	:	-	-	-	N	O
Week	NN	week	week	week	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBN	controlled	controlled	control	N	O
Studies	NNPS	studies	study	studi	N	O
Reported	VBD	reported	reported	report	N	O
in	IN	in	in	in	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
-	:	-	-	-	N	O
Treated	VBD	treated	treated	treat	N	O
PatientsThe	NNP	patientsthe	patientsthe	patientsth	N	O
four	CD	four	four	four	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
included	VBD	included	included	includ	N	O
one	CD	one	one	one	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
trial	NN	trial	trial	trial	N	O
and	CC	and	and	and	N	O
three	CD	three	three	three	N	O
add	SYM	add	add	add	Y	O
-	:	-	-	-	N	O
on	IN	on	on	on	N	O
combination	NN	combination	combination	combin	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
metformin	NN	metformin	metformin	metformin	N	O
,	,	,	,	,	N	O
metformin	NN	metformin	metformin	metformin	N	O
and	CC	and	and	and	N	O
sulfonylurea	NN	sulfonylurea	sulfonylurea	sulfonylurea	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
metformin	NN	metformin	metformin	metformin	N	O
and	CC	and	and	and	N	O
pioglitazone	NN	pioglitazone	pioglitazone	pioglitazon	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
PlaceboN	NNP	placebon	placebon	placebon	N	O
646	CD	646	646	646	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mgN	NN	mgn	mgn	mgn	N	O
833	CD	833	833	833	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mgN	NN	mgn	mgn	mgn	N	O
834	CD	834	834	834	N	O

Female	NN	female	female	femal	N	B-AdverseReaction

genital	JJ	genital	genital	genit	N	I-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
3.2%	CD	3.2%	3.2%	3.2%	N	O
10.4%	CD	10.4%	10.4%	10.4%	N	O
11.4%	CD	11.4%	11.4%	11.4%	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
4.0%	CD	4.0%	4.0%	4.0%	N	O
5.9%	CD	5.9%	5.9%	5.9%	N	O
4.3%	CD	4.3%	4.3%	4.3%	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
urination	NN	urination	urination	urin	N	I-AdverseReaction
0.8%	CD	0.8%	0.8%	0.8%	N	O
5.3%	CD	5.3%	5.3%	5.3%	N	O
4.6%	CD	4.6%	4.6%	4.6%	N	O

Male	JJ	male	male	male	N	B-AdverseReaction
genital	JJ	genital	genital	genit	N	I-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
0.6%	CD	0.6%	0.6%	0.6%	N	O
4.2%	CD	4.2%	4.2%	4.2%	N	O
3.7%	CD	3.7%	3.7%	3.7%	N	O

Vulvovaginal	NNP	vulvovaginal	vulvovaginal	vulvovagin	N	B-AdverseReaction
pruritus	NN	pruritus	pruritus	pruritu	Y	I-AdverseReaction
0.0%	CD	0.0%	0.0%	0.0%	N	O
1.6%	CD	1.6%	1.6%	1.6%	N	O
3.0%	CD	3.0%	3.0%	3.0%	N	O

Thirst	NNP	thirst	thirst	thirst	Y	B-AdverseReaction
0.2%	CD	0.2%	0.2%	0.2%	N	O
2.8%	CD	2.8%	2.8%	2.8%	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
0.9%	CD	0.9%	0.9%	0.9%	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
1.5%	CD	1.5%	1.5%	1.5%	N	O
2.2%	CD	2.2%	2.2%	2.2%	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
also	RB	also	also	also	N	O
more	JJR	more	more	more	N	O
commonly	RB	commonly	commonly	commonli	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
1.8%	CD	1.8%	1.8%	1.8%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
)	)	)	)	)	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
taking	VBG	taking	taking	take	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Pool	NN	pool	pool	pool	N	O

of	IN	of	of	of	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
and	CC	and	and	and	N	O
Active	NNP	active	active	activ	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O

The	DT	the	the	the	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
for	IN	for	for	for	N	O
canagliflozin	NN	canagliflozin	canagliflozin	canagliflozin	N	O
was	VBD	was	wa	wa	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
larger	JJR	larger	larger	larger	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
participating	VBG	participating	participating	particip	N	O
in	IN	in	in	in	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
and	CC	and	and	and	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
data	NN	data	data	data	N	O
combined	VBD	combined	combined	combin	N	O
eight	CD	eight	eight	eight	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
and	CC	and	and	and	N	O
reflect	JJ	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
of	IN	of	of	of	N	O
6177	CD	6177	6177	6177	N	O
patients	NNS	patients	patient	patient	N	O
to	TO	to	to	to	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
was	VBD	was	wa	wa	N	O
38	CD	38	38	38	N	O
weeks	NNS	weeks	week	week	N	O
with	IN	with	with	with	N	O
1832	CD	1832	1832	1832	N	O
individuals	NNS	individuals	individual	individu	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
for	IN	for	for	for	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
50	CD	50	50	50	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
3092	CD	3092	3092	3092	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
3085	CD	3085	3085	3085	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
comparator	NN	comparator	comparator	compar	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
3262	CD	3262	3262	3262	N	O
)	)	)	)	)	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
was	VBD	was	wa	wa	N	O
60	CD	60	60	60	N	O
years	NNS	years	year	year	N	O
and	CC	and	and	and	N	O
5%	CD	5%	5%	5%	N	O
were	VBD	were	were	were	N	O
older	JJR	older	older	older	N	O
than	IN	than	than	than	N	O
75	CD	75	75	75	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
.	.	.	.	.	N	O

Fifty	NNP	fifty	fifty	fifti	N	O
-	:	-	-	-	N	O
eight	CD	eight	eight	eight	N	O
percent	NN	percent	percent	percent	N	O
(	(	(	(	(	N	O
58%	CD	58%	58%	58%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
was	VBD	was	wa	wa	N	O
male	JJ	male	male	male	N	O
and	CC	and	and	and	N	O
73%	CD	73%	73%	73%	N	O
were	VBD	were	were	were	N	O
Caucasian	NNP	caucasian	caucasian	caucasian	N	O
,	,	,	,	,	N	O
16%	CD	16%	16%	16%	N	O
were	VBD	were	were	were	N	O
Asian	JJ	asian	asian	asian	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
4%	CD	4%	4%	4%	N	O
were	VBD	were	were	were	N	O
Black	NNP	black	black	black	N	O
or	CC	or	or	or	N	O
African	JJ	african	african	african	N	O
American	NNP	american	american	american	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
had	VBD	had	had	had	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
for	IN	for	for	for	N	O
an	DT	an	an	an	N	O
average	NN	average	average	averag	N	O
of	IN	of	of	of	N	O
11	CD	11	11	11	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
HbA1C	NNP	hba1c	hba1c	hba1c	Y	O
of	IN	of	of	of	N	O
8.0%	CD	8.0%	8.0%	8.0%	N	O
and	CC	and	and	and	N	O
33%	CD	33%	33%	33%	N	O
had	VBD	had	had	had	N	O
established	VBN	established	established	establish	N	O
microvascular	JJ	microvascular	microvascular	microvascular	N	O
complications	NNS	complications	complication	complic	N	O
of	IN	of	of	of	N	O
diabetes	NNS	diabetes	diabetes	diabet	Y	O
.	.	.	.	.	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
was	VBD	was	wa	wa	N	O
normal	JJ	normal	normal	normal	N	O
or	CC	or	or	or	N	O
mildly	RB	mildly	mildly	mildli	N	O
impaired	JJ	impaired	impaired	impair	N	O
(	(	(	(	(	N	O
mean	JJ	mean	mean	mean	N	O
eGFR	VBP	egfr	egfr	egfr	N	O
81	CD	81	81	81	N	O
mL	NNS	ml	ml	ml	N	O
min	RB	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NNS	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
types	NNS	types	type	type	N	O
and	CC	and	and	and	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
eight	CD	eight	eight	eight	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
were	VBD	were	were	were	N	O
consistent	JJ	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
those	DT	those	those	those	N	O
listed	VBN	listed	listed	list	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
this	DT	this	this	thi	N	O
pool	NN	pool	pool	pool	N	O
,	,	,	,	,	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
was	VBD	was	wa	wa	N	O
also	RB	also	also	also	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
(	(	(	(	(	N	O
1.7%	CD	1.7%	1.7%	1.7%	N	O
with	IN	with	with	with	N	O
comparator	NN	comparator	comparator	compar	N	O
,	,	,	,	,	N	O
2.2%	CD	2.2%	2.2%	2.2%	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
2.0%	CD	2.0%	2.0%	2.0%	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
loss	NN	loss	loss	loss	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
strength	NN	strength	strength	strength	N	I-AdverseReaction
or	CC	or	or	or	N	O
energy	NN	energy	energy	energi	N	I-AdverseReaction
(	(	(	(	(	N	O
i	JJ	i	i	i	N	O
.	.	.	.	.	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
)	)	)	)	)	N	O
(	(	(	(	(	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
with	IN	with	with	with	N	O
comparator	NN	comparator	comparator	compar	N	O
,	,	,	,	,	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
1.1%	CD	1.1%	1.1%	1.1%	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
eight	CD	eight	eight	eight	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction
(	(	(	(	(	N	O
acute	JJ	acute	acute	acut	N	I-AdverseReaction
or	CC	or	or	or	N	O
chronic	JJ	chronic	chronic	chronic	N	I-AdverseReaction
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
0.9	CD	0.9	0.9	0.9	N	O
,	,	,	,	,	N	O
2.7	CD	2.7	2.7	2.7	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
0.9	CD	0.9	0.9	0.9	N	O
per	IN	per	per	per	N	O
1000	CD	1000	1000	1000	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
comparator	NN	comparator	comparator	compar	N	O
,	,	,	,	,	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
eight	CD	eight	eight	eight	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
,	,	,	,	,	N	O
urticaria	NN	urticaria	urticaria	urticaria	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
angioedema	NN	angioedema	angioedema	angioedema	Y	B-AdverseReaction
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
3.0%	CD	3.0%	3.0%	3.0%	N	O
,	,	,	,	,	N	O
3.8%	CD	3.8%	3.8%	3.8%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
4.2%	CD	4.2%	4.2%	4.2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
comparator	NN	comparator	comparator	compar	N	O
,	,	,	,	,	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Five	CD	five	five	five	N	O
patients	NNS	patients	patient	patient	N	O
experienced	VBD	experienced	experienced	experienc	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
of	IN	of	of	of	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
included	VBD	included	included	includ	N	O
4	CD	4	4	4	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
urticaria	JJ	urticaria	urticaria	urticaria	Y	B-AdverseReaction
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
patient	NN	patient	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
diffuse	NN	diffuse	diffuse	diffus	N	B-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
and	CC	and	and	and	N	O
urticaria	JJ	urticaria	urticaria	urticaria	Y	B-AdverseReaction
occurring	VBG	occurring	occurring	occur	N	O
within	IN	within	within	within	N	O
hours	NNS	hours	hour	hour	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
.	.	.	.	.	N	O

Among	IN	among	among	among	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
2	CD	2	2	2	N	O
patients	NNS	patients	patient	patient	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
.	.	.	.	.	N	O

One	CD	one	one	one	N	O
patient	NN	patient	patient	patient	N	O
with	IN	with	with	with	N	O
urticaria	NNS	urticaria	urticaria	urticaria	Y	B-AdverseReaction
had	VBD	had	had	had	N	O
recurrence	NN	recurrence	recurrence	recurr	N	O
when	WRB	when	when	when	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
was	VBD	was	wa	wa	N	O
re	JJ	re	re	re	N	O
-	:	-	-	-	N	O
initiated	VBN	initiated	initiated	initi	N	O
.	.	.	.	.	N	O

Photosensitivity	NNP	photosensitivity	photosensitivity	photosensit	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
photosensitivity	NN	photosensitivity	photosensitivity	photosensit	Y	B-AdverseReaction
reaction	NN	reaction	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
polymorphic	JJ	polymorphic	polymorphic	polymorph	N	B-AdverseReaction
light	JJ	light	light	light	N	I-AdverseReaction
eruption	NN	eruption	eruption	erupt	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
sunburn	NN	sunburn	sunburn	sunburn	Y	B-AdverseReaction
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
,	,	,	,	,	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
comparator	NN	comparator	comparator	compar	N	O
,	,	,	,	,	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
more	RBR	more	more	more	N	O
frequently	RB	frequently	frequently	frequent	N	O
on	IN	on	on	on	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
than	IN	than	than	than	N	O
on	IN	on	on	on	N	O
comparator	NN	comparator	comparator	compar	N	O
were	VBD	were	were	were	N	O
:	:	:	:	:	N	O

Volume	NN	volume	volume	volum	N	O
Depletion	NNP	depletion	depletion	deplet	N	O
-	:	-	-	-	N	O
Related	JJ	related	related	relat	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O

INVOKANA	NNP	invokana	invokana	invokana	N	O
results	NNS	results	result	result	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
osmotic	JJ	osmotic	osmotic	osmot	N	B-AdverseReaction
diuresis	NN	diuresis	diuresis	diuresi	Y	I-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
may	MD	may	may	may	N	B-Factor
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
reductions	NNS	reductions	reduction	reduct	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
intravascular	JJ	intravascular	intravascular	intravascular	N	I-AdverseReaction
volume	NN	volume	volume	volum	N	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
was	VBD	was	wa	wa	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
dependent	JJ	dependent	dependent	depend	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
volume	NN	volume	volume	volum	N	B-AdverseReaction
depletion	NN	depletion	depletion	deplet	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
,	,	,	,	,	N	O
postural	JJ	postural	postural	postur	N	B-AdverseReaction
dizziness	NN	dizziness	dizziness	dizzi	Y	I-AdverseReaction
,	,	,	,	,	N	O
orthostatic	JJ	orthostatic	orthostatic	orthostat	N	B-AdverseReaction
hypotension	NN	hypotension	hypotension	hypotens	Y	I-AdverseReaction
,	,	,	,	,	N	O
syncope	NN	syncope	syncope	syncop	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

An	DT	an	an	an	N	O
increased	JJ	increased	increased	increas	N	O
incidence	NN	incidence	incidence	incid	N	O
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
three	CD	three	three	three	N	O
factors	NNS	factors	factor	factor	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
largest	JJS	largest	largest	largest	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
volume	NN	volume	volume	volum	N	B-AdverseReaction
depletion	NN	depletion	depletion	deplet	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
were	VBD	were	were	were	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
loop	NN	loop	loop	loop	N	O
diuretics	NNS	diuretics	diuretic	diuret	N	O
,	,	,	,	,	N	O
moderate	JJ	moderate	moderate	moder	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
(	(	(	(	(	N	O
eGFR	JJ	egfr	egfr	egfr	N	O
30	CD	30	30	30	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
60	CD	60	60	60	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
age	NN	age	age	age	N	O
75	CD	75	75	75	N	O
years	NNS	years	year	year	N	O
and	CC	and	and	and	N	O
older	JJR	older	older	older	N	O
(	(	(	(	(	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.5	CD	8.5	8.5	8.5	N	O
and	CC	and	and	and	N	O
8.6	CD	8.6	8.6	8.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
With	IN	with	with	with	N	O
at	IN	at	at	at	N	O
Least	NNP	least	least	least	N	O
One	CD	one	one	one	N	O
Volume	NN	volume	volume	volum	N	B-AdverseReaction
Depletion	NNP	depletion	depletion	deplet	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Related	JJ	related	related	relat	N	I-AdverseReaction
Adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
Reaction	NNP	reaction	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
Pooled	VBN	pooled	pooled	pool	N	O
Results	NNS	results	result	result	N	O
from	IN	from	from	from	N	O
8	CD	8	8	8	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
)	)	)	)	)	N	O

Baseline	NNP	baseline	baseline	baselin	N	O
Characteristic	NNP	characteristic	characteristic	characterist	N	O
Comparator	NNP	comparator	comparator	compar	N	O
Group	NNP	group	group	group	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O

Overall	JJ	overall	overall	overal	N	O

population	NN	population	population	popul	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
2.3%	CD	2.3%	2.3%	2.3%	N	O
3.4%	CD	3.4%	3.4%	3.4%	N	O

75	CD	75	75	75	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
and	CC	and	and	and	N	O
older	JJR	older	older	older	N	O
2.6%	CD	2.6%	2.6%	2.6%	N	O
4.9%	CD	4.9%	4.9%	4.9%	N	O
8.7%	CD	8.7%	8.7%	8.7%	N	O

eGFR	RB	egfr	egfr	egfr	N	B-AdverseReaction
less	JJR	less	le	less	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
60	CD	60	60	60	N	I-AdverseReaction
mL	JJ	ml	ml	ml	N	I-AdverseReaction
min	NN	min	min	min	N	I-AdverseReaction
1.73	CD	1.73	1.73	1.73	N	I-AdverseReaction
m	NN	m	m	m	N	I-AdverseReaction
2	CD	2	2	2	N	I-AdverseReaction
2.5%	CD	2.5%	2.5%	2.5%	N	O
4.7%	CD	4.7%	4.7%	4.7%	N	O
8.1%	CD	8.1%	8.1%	8.1%	N	O

Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
loop	NN	loop	loop	loop	N	O
diuretic	JJ	diuretic	diuretic	diuret	N	O
4.7%	CD	4.7%	4.7%	4.7%	N	O
3.2%	CD	3.2%	3.2%	3.2%	N	O
8.8%	CD	8.8%	8.8%	8.8%	N	O

Falls	NNS	falls	fall	fall	N	O

In	IN	in	in	in	N	O

a	DT	a	a	a	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
nine	CD	nine	nine	nine	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
mean	JJ	mean	mean	mean	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
of	IN	of	of	of	N	O
85	CD	85	85	85	N	O
weeks	NNS	weeks	week	week	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
experienced	VBD	experienced	experienced	experienc	N	O
falls	NNS	falls	fall	fall	N	B-AdverseReaction
was	VBD	was	wa	wa	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O
,	,	,	,	,	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
2.1%	CD	2.1%	2.1%	2.1%	N	O
with	IN	with	with	with	N	O
comparator	NN	comparator	comparator	compar	N	O
,	,	,	,	,	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
higher	JJR	higher	higher	higher	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
falls	NNS	falls	fall	fall	N	B-AdverseReaction
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
few	JJ	few	few	few	N	O
weeks	NNS	weeks	week	week	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Impairment	NN	impairment	impairment	impair	N	O
in	IN	in	in	in	N	O
Renal	NNP	renal	renal	renal	N	O
Function	NNP	function	function	function	N	O

INVOKANA	NNP	invokana	invokana	invokana	N	O
is	VBZ	is	is	is	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
dependent	JJ	dependent	dependent	depend	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
and	CC	and	and	and	N	O
a	DT	a	a	a	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
fall	NN	fall	fall	fall	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
estimated	VBN	estimated	estimated	estim	N	I-AdverseReaction
GFR	NNP	gfr	gfr	gfr	Y	I-AdverseReaction
(	(	(	(	(	N	O
Table	NNP	table	table	tabl	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
had	VBD	had	had	had	N	O
larger	JJR	larger	larger	larger	N	O
mean	JJ	mean	mean	mean	N	O
changes	NNS	changes	change	chang	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
:	:	:	:	:	N	O
Changes	NNS	changes	change	chang	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
Serum	NNP	serum	serum	serum	N	I-AdverseReaction
Creatinine	NNP	creatinine	creatinine	creatinin	Y	I-AdverseReaction
and	CC	and	and	and	N	O
eGFR	RB	egfr	egfr	egfr	N	I-AdverseReaction
Associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Pool	NNP	pool	pool	pool	N	O
of	IN	of	of	of	N	O
Four	NNP	four	four	four	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBN	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
Moderate	NNP	moderate	moderate	moder	N	O
Renal	NNP	renal	renal	renal	N	O
Impairment	NNP	impairment	impairment	impair	N	O
Trial	NNP	trial	trial	trial	N	O

PlaceboN	NNP	placebon	placebon	placebon	N	O
646	CD	646	646	646	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mgN	NN	mgn	mgn	mgn	N	O
833	CD	833	833	833	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mgN	NN	mgn	mgn	mgn	N	O
834	CD	834	834	834	N	O

Pool	NNP	pool	pool	pool	N	O
of	IN	of	of	of	N	O
Four	NNP	four	four	four	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
Controlled	VBD	controlled	controlled	control	N	O
Trials	NNS	trials	trial	trial	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
0.84	CD	0.84	0.84	0.84	N	O
0.82	CD	0.82	0.82	0.82	N	O
0.82	CD	0.82	0.82	0.82	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
87.0	CD	87.0	87.0	87.0	N	O
88.3	CD	88.3	88.3	88.3	N	O
88.8	CD	88.8	88.8	88.8	N	O

Week	JJ	week	week	week	N	O
6	CD	6	6	6	N	O
Change	NNP	change	change	chang	N	O
Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
0.01	CD	0.01	0.01	0.01	N	O
0.03	CD	0.03	0.03	0.03	N	O
0.05	CD	0.05	0.05	0.05	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
1.6	CD	1.6	1.6	1.6	N	O
-	:	-	-	-	N	O
3.8	CD	3.8	3.8	3.8	N	O
-	:	-	-	-	N	O
5.0	CD	5.0	5.0	5.0	N	O

End	NN	end	end	end	N	O
of	IN	of	of	of	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
Change	NNP	change	change	chang	N	O
Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
0.01	CD	0.01	0.01	0.01	N	O
0.02	CD	0.02	0.02	0.02	N	O
0.03	CD	0.03	0.03	0.03	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
1.6	CD	1.6	1.6	1.6	N	O
-	:	-	-	-	N	O
2.3	CD	2.3	2.3	2.3	N	O
-	:	-	-	-	N	O
3.4	CD	3.4	3.4	3.4	N	O

PlaceboN	NNP	placebon	placebon	placebon	N	O
90	CD	90	90	90	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mgN	NN	mgn	mgn	mgn	N	O
90	CD	90	90	90	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mgN	NN	mgn	mgn	mgn	N	O
89	CD	89	89	89	N	O

Moderate	NNP	moderate	moderate	moder	N	O
Renal	NNP	renal	renal	renal	N	O
Impairment	NNP	impairment	impairment	impair	N	O
Trial	NNP	trial	trial	trial	N	O
Baseline	NNP	baseline	baseline	baselin	N	O
Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
1.61	CD	1.61	1.61	1.61	N	O
1.62	CD	1.62	1.62	1.62	N	O
1.63	CD	1.63	1.63	1.63	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
40.1	CD	40.1	40.1	40.1	N	O
39.7	CD	39.7	39.7	39.7	N	O
38.5	CD	38.5	38.5	38.5	N	O

Week	JJ	week	week	week	N	O
3	CD	3	3	3	N	O
Change	NNP	change	change	chang	N	O
Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
0.03	CD	0.03	0.03	0.03	N	O
0.18	CD	0.18	0.18	0.18	N	O
0.28	CD	0.28	0.28	0.28	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
0.7	CD	0.7	0.7	0.7	N	O
-	:	-	-	-	N	O
4.6	CD	4.6	4.6	4.6	N	O
-	:	-	-	-	N	O
6.2	CD	6.2	6.2	6.2	N	O

End	NN	end	end	end	N	O
of	IN	of	of	of	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
Change	NNP	change	change	chang	N	O
Creatinine	NNP	creatinine	creatinine	creatinin	Y	O
(	(	(	(	(	N	O
mg	FW	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
0.07	CD	0.07	0.07	0.07	N	O
0.16	CD	0.16	0.16	0.16	N	O
0.18	CD	0.18	0.18	0.18	N	O

eGFR	NN	egfr	egfr	egfr	N	O
(	(	(	(	(	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
-	:	-	-	-	N	O
1.5	CD	1.5	1.5	1.5	N	O
-	:	-	-	-	N	O
3.6	CD	3.6	3.6	3.6	N	O
-	:	-	-	-	N	O
4.0	CD	4.0	4.0	4.0	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
four	CD	four	four	four	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
where	WRB	where	where	where	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
normal	JJ	normal	normal	normal	N	O
or	CC	or	or	or	N	O
mildly	RB	mildly	mildly	mildli	N	O
impaired	JJ	impaired	impaired	impair	N	O
baseline	NN	baseline	baseline	baselin	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
experienced	VBD	experienced	experienced	experienc	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
significant	JJ	significant	significant	signific	N	B-Severity
renal	JJ	renal	renal	renal	N	B-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
decline	NN	decline	decline	declin	N	I-AdverseReaction
,	,	,	,	,	N	O
defined	VBD	defined	defined	defin	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
eGFR	NN	egfr	egfr	egfr	N	B-AdverseReaction
below	IN	below	below	below	N	I-AdverseReaction
80	CD	80	80	80	N	I-AdverseReaction
mL	NNS	ml	ml	ml	N	I-AdverseReaction
min	RB	min	min	min	N	I-AdverseReaction
1.73	CD	1.73	1.73	1.73	N	I-AdverseReaction
m	NNS	m	m	m	N	I-AdverseReaction
2	CD	2	2	2	N	I-AdverseReaction
and	CC	and	and	and	N	O
30%	CD	30%	30%	30%	N	I-AdverseReaction
lower	JJR	lower	lower	lower	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
baseline	NN	baseline	baseline	baselin	N	I-AdverseReaction
,	,	,	,	,	N	O
was	VBD	was	wa	wa	N	O
2.1%	CD	2.1%	2.1%	2.1%	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
2.0%	CD	2.0%	2.0%	2.0%	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
4.1%	CD	4.1%	4.1%	4.1%	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
the	DT	the	the	the	N	O
end	NN	end	end	end	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
1.4%	CD	1.4%	1.4%	1.4%	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
significant	JJ	significant	significant	signific	N	B-Severity
renal	JJ	renal	renal	renal	N	B-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
decline	NN	decline	decline	declin	N	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O

a	DT	a	a	a	N	O
trial	NN	trial	trial	trial	N	O
carried	VBD	carried	carried	carri	N	O
out	RP	out	out	out	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
baseline	NN	baseline	baseline	baselin	N	O
eGFR	NN	egfr	egfr	egfr	N	O
of	IN	of	of	of	N	O
30	CD	30	30	30	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
50	CD	50	50	50	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
mean	JJ	mean	mean	mean	N	O
baseline	NN	baseline	baseline	baselin	N	O
eGFR	NN	egfr	egfr	egfr	N	O
39	CD	39	39	39	N	O
mL	NN	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.3	CD	14.3	14.3	14.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
proportion	NN	proportion	proportion	proport	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
experienced	VBD	experienced	experienced	experienc	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
significant	JJ	significant	significant	signific	N	B-Severity
renal	JJ	renal	renal	renal	N	B-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
decline	NN	decline	decline	declin	N	I-AdverseReaction
,	,	,	,	,	N	O
defined	VBD	defined	defined	defin	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
eGFR	NN	egfr	egfr	egfr	N	B-AdverseReaction
30%	CD	30%	30%	30%	N	I-AdverseReaction
lower	JJR	lower	lower	lower	N	I-AdverseReaction
than	IN	than	than	than	N	I-AdverseReaction
baseline	NN	baseline	baseline	baselin	N	I-AdverseReaction
,	,	,	,	,	N	O
was	VBD	was	wa	wa	N	O
6.9%	CD	6.9%	6.9%	6.9%	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
18%	CD	18%	18%	18%	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
22.5%	CD	22.5%	22.5%	22.5%	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
the	DT	the	the	the	N	O
end	NN	end	end	end	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
4.6%	CD	4.6%	4.6%	4.6%	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
3.4%	CD	3.4%	3.4%	3.4%	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
2.2%	CD	2.2%	2.2%	2.2%	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
significant	JJ	significant	significant	signific	N	B-Severity
renal	JJ	renal	renal	renal	N	B-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
decline	NN	decline	decline	declin	N	I-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
pooled	JJ	pooled	pooled	pool	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
1085	CD	1085	1085	1085	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
baseline	NN	baseline	baseline	baselin	N	O
eGFR	NN	egfr	egfr	egfr	N	O
of	IN	of	of	of	N	O
30	CD	30	30	30	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
60	CD	60	60	60	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
mean	JJ	mean	mean	mean	N	O
baseline	NN	baseline	baseline	baselin	N	O
eGFR	NN	egfr	egfr	egfr	N	O
48	CD	48	48	48	N	O
mL	NN	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
overall	JJ	overall	overall	overal	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
was	VBD	was	wa	wa	N	O
lower	JJR	lower	lower	lower	N	O
than	IN	than	than	than	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
dedicated	JJ	dedicated	dedicated	dedic	N	O
trial	NN	trial	trial	trial	N	O
but	CC	but	but	but	N	O
a	DT	a	a	a	N	O
dose	JJ	dose	dose	dose	N	O
-	:	-	-	-	N	O
dependent	JJ	dependent	dependent	depend	N	O
increase	NN	increase	increase	increas	N	O
in	IN	in	in	in	N	O
incident	JJ	incident	incident	incid	N	O
episodes	NNS	episodes	episode	episod	N	O
of	IN	of	of	of	N	O
significant	JJ	significant	significant	signific	N	B-Severity
renal	JJ	renal	renal	renal	N	B-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
decline	NN	decline	decline	declin	N	I-AdverseReaction
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
was	VBD	was	wa	wa	N	O
still	RB	still	still	still	N	O
observed	VBN	observed	observed	observ	N	O
.	.	.	.	.	N	O

Use	NNP	use	use	use	N	O
of	IN	of	of	of	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
increased	JJ	increased	increased	increas	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
,	,	,	,	,	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
glomerular	JJ	glomerular	glomerular	glomerular	N	I-AdverseReaction
filtration	NN	filtration	filtration	filtrat	N	I-AdverseReaction
rate	NN	rate	rate	rate	N	I-AdverseReaction
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pooled	JJ	pooled	pooled	pool	N	O
analysis	NN	analysis	analysis	analysi	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
3.7%	CD	3.7%	3.7%	3.7%	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
8.9%	CD	8.9%	8.9%	8.9%	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
9.3%	CD	9.3%	9.3%	9.3%	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
.	.	.	.	.	N	O

Discontinuations	NNS	discontinuations	discontinuation	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
1.0%	CD	1.0%	1.0%	1.0%	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
1.2%	CD	1.2%	1.2%	1.2%	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
1.6%	CD	1.6%	1.6%	1.6%	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Genital	NNP	genital	genital	genit	N	O
Mycotic	NNP	mycotic	mycotic	mycot	N	O
Infections	NNP	infections	infection	infect	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
four	CD	four	four	four	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
female	JJ	female	female	femal	N	B-AdverseReaction
genital	JJ	genital	genital	genit	N	I-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
vulvovaginal	JJ	vulvovaginal	vulvovaginal	vulvovagin	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
vulvovaginal	JJ	vulvovaginal	vulvovaginal	vulvovagin	N	B-AdverseReaction
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vulvovaginitis	NN	vulvovaginitis	vulvovaginitis	vulvovagin	Y	B-AdverseReaction
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
3.2%	CD	3.2%	3.2%	3.2%	N	O
,	,	,	,	,	N	O
10.4%	CD	10.4%	10.4%	10.4%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
11.4%	CD	11.4%	11.4%	11.4%	N	O
of	IN	of	of	of	N	O
females	NNS	females	female	femal	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
genital	JJ	genital	genital	genit	N	O
mycotic	JJ	mycotic	mycotic	mycot	N	O
infections	NNS	infections	infection	infect	N	O
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
likely	JJ	likely	likely	like	N	O
to	TO	to	to	to	N	O
develop	VB	develop	develop	develop	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
on	IN	on	on	on	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
.	.	.	.	.	N	O

Female	JJ	female	female	femal	N	B-AdverseReaction
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
developed	VBD	developed	developed	develop	N	O
genital	JJ	genital	genital	genit	N	I-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
on	IN	on	on	on	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
likely	JJ	likely	likely	like	N	O
to	TO	to	to	to	N	O
experience	VB	experience	experience	experi	N	O
recurrence	NN	recurrence	recurrence	recurr	N	O
and	CC	and	and	and	N	O
require	VB	require	require	requir	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
oral	JJ	oral	oral	oral	N	O
or	CC	or	or	or	N	O
topical	JJ	topical	topical	topic	N	O
antifungal	JJ	antifungal	antifungal	antifung	N	O
agents	NNS	agents	agent	agent	N	O
and	CC	and	and	and	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
microbial	JJ	microbial	microbial	microbi	N	O
agents	NNS	agents	agent	agent	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
females	NNS	females	female	femal	N	B-AdverseReaction
,	,	,	,	,	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
genital	JJ	genital	genital	genit	N	I-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0%	CD	0%	0%	0%	N	O
and	CC	and	and	and	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
four	CD	four	four	four	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
male	JJ	male	male	male	N	B-AdverseReaction
genital	JJ	genital	genital	genit	N	I-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
candidal	JJ	candidal	candidal	candid	N	B-AdverseReaction
balanitis	NN	balanitis	balanitis	balan	Y	I-AdverseReaction
,	,	,	,	,	N	O
balanoposthitis	NN	balanoposthitis	balanoposthitis	balanoposth	Y	B-AdverseReaction
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
,	,	,	,	,	N	O
4.2%	CD	4.2%	4.2%	4.2%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
3.7%	CD	3.7%	3.7%	3.7%	N	O
of	IN	of	of	of	N	O
males	NNS	males	male	male	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Male	JJ	male	male	male	N	B-AdverseReaction
genital	JJ	genital	genital	genit	N	I-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
more	RBR	more	more	more	N	O
commonly	RB	commonly	commonly	commonli	N	O
in	IN	in	in	in	N	O
uncircumcised	JJ	uncircumcised	uncircumcised	uncircumcis	Y	O
males	NNS	males	male	male	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
males	NNS	males	male	male	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
prior	JJ	prior	prior	prior	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
balanitis	NN	balanitis	balanitis	balan	Y	O
or	CC	or	or	or	N	O
balanoposthitis	NN	balanoposthitis	balanoposthitis	balanoposth	Y	O
.	.	.	.	.	N	O

Male	JJ	male	male	male	N	B-AdverseReaction
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
developed	VBD	developed	developed	develop	N	O
genital	JJ	genital	genital	genit	N	I-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
on	IN	on	on	on	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
likely	JJ	likely	likely	like	N	O
to	TO	to	to	to	N	O
experience	VB	experience	experience	experi	N	O
recurrent	JJ	recurrent	recurrent	recurr	N	O
infections	NNS	infections	infection	infect	N	O
(	(	(	(	(	N	O
22%	CD	22%	22%	22%	N	O
on	IN	on	on	on	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
versus	NN	versus	versus	versu	N	O
none	NN	none	none	none	N	O
on	IN	on	on	on	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
require	VB	require	require	requir	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
oral	JJ	oral	oral	oral	N	O
or	CC	or	or	or	N	O
topical	JJ	topical	topical	topic	N	O
antifungal	JJ	antifungal	antifungal	antifung	N	O
agents	NNS	agents	agent	agent	N	O
and	CC	and	and	and	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
microbial	NN	microbial	microbial	microbi	N	O
agents	NNS	agents	agent	agent	N	O
than	IN	than	than	than	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
comparators	NNS	comparators	comparators	compar	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
males	NNS	males	male	male	N	B-AdverseReaction
,	,	,	,	,	N	O
discontinuations	NNS	discontinuations	discontinuation	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
genital	JJ	genital	genital	genit	N	I-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0%	CD	0%	0%	0%	N	O
and	CC	and	and	and	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
and	CC	and	and	and	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pooled	JJ	pooled	pooled	pool	N	O
analysis	NN	analysis	analysis	analysi	N	O
of	IN	of	of	of	N	O
8	CD	8	8	8	N	O
controlled	JJ	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
phimosis	NN	phimosis	phimosis	phimosi	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
of	IN	of	of	of	N	O
uncircumcised	JJ	uncircumcised	uncircumcised	uncircumcis	Y	O
male	NN	male	male	male	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
and	CC	and	and	and	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
required	VBN	required	required	requir	N	O
circumcision	NN	circumcision	circumcision	circumcis	Y	O
to	TO	to	to	to	N	O
treat	VB	treat	treat	treat	N	O
the	DT	the	the	the	N	O
phimosis	NN	phimosis	phimosis	phimosi	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O

In	IN	in	in	in	N	O
all	DT	all	all	all	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
was	VBD	was	wa	wa	N	O
defined	VBN	defined	defined	defin	N	O
as	IN	as	a	as	N	O
any	DT	any	any	ani	N	O
event	NN	event	event	event	N	O
regardless	NN	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
,	,	,	,	,	N	O
where	WRB	where	where	where	N	O
biochemical	JJ	biochemical	biochemical	biochem	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
was	VBD	was	wa	wa	N	O
documented	VBN	documented	documented	document	N	O
(	(	(	(	(	N	O
any	DT	any	any	ani	N	O
glucose	NN	glucose	glucose	glucos	Y	O
value	NN	value	value	valu	N	O
below	IN	below	below	below	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
70	CD	70	70	70	N	O
mg	NNS	mg	mg	mg	N	O
dL	NN	dl	dl	dl	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Severe	NNP	severe	severe	sever	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
was	VBD	was	wa	wa	N	O
defined	VBN	defined	defined	defin	N	O
as	IN	as	a	as	N	O
an	DT	an	an	an	N	O
event	NN	event	event	event	N	O
consistent	NN	consistent	consistent	consist	N	O
with	IN	with	with	with	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
where	WRB	where	where	where	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
required	VBD	required	required	requir	N	O
the	DT	the	the	the	N	O
assistance	NN	assistance	assistance	assist	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
person	NN	person	person	person	N	O
to	TO	to	to	to	N	O
recover	VB	recover	recover	recov	N	O
,	,	,	,	,	N	O
lost	VBN	lost	lost	lost	N	O
consciousness	NN	consciousness	consciousness	conscious	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
seizure	NN	seizure	seizure	seizur	Y	O
(	(	(	(	(	N	O
regardless	NN	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
whether	IN	whether	whether	whether	N	O
biochemical	JJ	biochemical	biochemical	biochem	N	O
documentation	NN	documentation	documentation	document	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
low	JJ	low	low	low	N	O
glucose	NN	glucose	glucose	glucos	Y	O
value	NN	value	value	valu	N	O
was	VBD	was	wa	wa	N	O
obtained	VBN	obtained	obtained	obtain	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
individual	JJ	individual	individual	individu	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
,	,	,	,	,	N	O
episodes	NNS	episodes	episode	episod	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
rate	NN	rate	rate	rate	N	O
when	WRB	when	when	when	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
was	VBD	was	wa	wa	N	O
co	JJ	co	co	co	N	O
-	:	-	-	-	N	O
administered	VBN	administered	administered	administ	N	O
with	IN	with	with	with	N	O
insulin	NN	insulin	insulin	insulin	Y	O
or	CC	or	or	or	N	O
sulfonylureas	NNS	sulfonylureas	sulfonylurea	sulfonylurea	N	O
(	(	(	(	(	N	O
Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
:	:	:	:	:	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
HypoglycemiaNumber	NNP	hypoglycemianumber	hypoglycemianumber	hypoglycemianumb	N	B-AdverseReaction
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
either	DT	either	either	either	N	O
biochemically	RB	biochemically	biochemically	biochem	N	O
documented	VBN	documented	documented	document	N	O
episodes	NNS	episodes	episode	episod	N	O
or	CC	or	or	or	N	O
severe	JJ	severe	severe	sever	N	B-Severity
hypoglycemic	JJ	hypoglycemic	hypoglycemic	hypoglycem	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
intent	NN	intent	intent	intent	N	O
-	:	-	-	-	N	O
to	TO	to	to	to	N	O
-	:	-	-	-	N	O
treat	NN	treat	treat	treat	N	O
population	NN	population	population	popul	N	O
in	IN	in	in	in	N	O
Controlled	NNP	controlled	controlled	control	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Studies	NNS	studies	study	studi	N	O

Monotherapy	NNP	monotherapy	monotherapy	monotherapi	N	O
(	(	(	(	(	N	O
26	CD	26	26	26	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
192	CD	192	192	192	N	O
)	)	)	)	)	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
195	CD	195	195	195	N	O
)	)	)	)	)	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
197	CD	197	197	197	N	O
)	)	)	)	)	N	O

Overall	JJ	overall	overall	overal	N	O

[	NN	[	[	[	N	O
N	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
2.6	CD	2.6	2.6	2.6	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
3.6	CD	3.6	3.6	3.6	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
3.0	CD	3.0	3.0	3.0	N	O
)	)	)	)	)	N	O

In	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
with	IN	with	with	with	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
26	CD	26	26	26	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
183	CD	183	183	183	N	O
)	)	)	)	)	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
368	CD	368	368	368	N	O
)	)	)	)	)	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
367	CD	367	367	367	N	O
)	)	)	)	)	N	O

Overall	JJ	overall	overall	overal	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
1.6	CD	1.6	1.6	1.6	N	O
)	)	)	)	)	N	O
16	CD	16	16	16	N	O
(	(	(	(	(	N	O
4.3	CD	4.3	4.3	4.3	N	O
)	)	)	)	)	N	O
17	CD	17	17	17	N	O
(	(	(	(	(	N	O
4.6	CD	4.6	4.6	4.6	N	O
)	)	)	)	)	N	O

Severe	NNP	severe	severe	sever	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
0	CD	0	0	0	N	O
(	(	(	(	(	N	O
0	CD	0	0	0	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.3	CD	0.3	0.3	0.3	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.3	CD	0.3	0.3	0.3	N	O
)	)	)	)	)	N	O

In	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
with	IN	with	with	with	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
52	CD	52	52	52	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
Glimepiride	NNP	glimepiride	glimepiride	glimepirid	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
482	CD	482	482	482	N	O
)	)	)	)	)	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
483	CD	483	483	483	N	O
)	)	)	)	)	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
485	CD	485	485	485	N	O
)	)	)	)	)	N	O

Overall	JJ	overall	overall	overal	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
165	CD	165	165	165	N	O
(	(	(	(	(	N	O
34.2	CD	34.2	34.2	34.2	N	O
)	)	)	)	)	N	O
27	CD	27	27	27	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
24	CD	24	24	24	N	O
(	(	(	(	(	N	O
4.9	CD	4.9	4.9	4.9	N	O
)	)	)	)	)	N	O

Severe	NNP	severe	severe	sever	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
15	CD	15	15	15	N	O
(	(	(	(	(	N	O
3.1	CD	3.1	3.1	3.1	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
0.4	CD	0.4	0.4	0.4	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
0.6	CD	0.6	0.6	0.6	N	O
)	)	)	)	)	N	O

In	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
with	IN	with	with	with	N	O
Sulfonylurea	NNP	sulfonylurea	sulfonylurea	sulfonylurea	N	O
(	(	(	(	(	N	O
18	CD	18	18	18	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Sulfonylurea	NNP	sulfonylurea	sulfonylurea	sulfonylurea	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
69	CD	69	69	69	N	O
)	)	)	)	)	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
Sulfonylurea	NNP	sulfonylurea	sulfonylurea	sulfonylurea	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
74	CD	74	74	74	N	O
)	)	)	)	)	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
Sulfonylurea	NNP	sulfonylurea	sulfonylurea	sulfonylurea	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
72	CD	72	72	72	N	O
)	)	)	)	)	N	O

Overall	JJ	overall	overall	overal	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
4.1	CD	4.1	4.1	4.1	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
12.5	CD	12.5	12.5	12.5	N	O
)	)	)	)	)	N	O

In	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
with	IN	with	with	with	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
Sulfonylurea	NNP	sulfonylurea	sulfonylurea	sulfonylurea	N	O
(	(	(	(	(	N	O
26	CD	26	26	26	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
Sulfonylurea	NNP	sulfonylurea	sulfonylurea	sulfonylurea	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
156	CD	156	156	156	N	O
)	)	)	)	)	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
Sulfonylurea	NNP	sulfonylurea	sulfonylurea	sulfonylurea	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
157	CD	157	157	157	N	O
)	)	)	)	)	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
Sulfonylurea	NNP	sulfonylurea	sulfonylurea	sulfonylurea	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
156	CD	156	156	156	N	O
)	)	)	)	)	N	O

Overall	JJ	overall	overall	overal	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
24	CD	24	24	24	N	O
(	(	(	(	(	N	O
15.4	CD	15.4	15.4	15.4	N	O
)	)	)	)	)	N	O
43	CD	43	43	43	N	O
(	(	(	(	(	N	O
27.4	CD	27.4	27.4	27.4	N	O
)	)	)	)	)	N	O
47	CD	47	47	47	N	O
(	(	(	(	(	N	O
30.1	CD	30.1	30.1	30.1	N	O
)	)	)	)	)	N	O

Severe	NNP	severe	severe	sever	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.6	CD	0.6	0.6	0.6	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
0.6	CD	0.6	0.6	0.6	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

In	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
with	IN	with	with	with	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
Sulfonylurea	NNP	sulfonylurea	sulfonylurea	sulfonylurea	N	O
(	(	(	(	(	N	O
52	CD	52	52	52	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
Sitagliptin	NNP	sitagliptin	sitagliptin	sitagliptin	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
Sulfonylurea	NNP	sulfonylurea	sulfonylurea	sulfonylurea	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
378	CD	378	378	378	N	O
)	)	)	)	)	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
Sulfonylurea	NNP	sulfonylurea	sulfonylurea	sulfonylurea	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
377	CD	377	377	377	N	O
)	)	)	)	)	N	O

Overall	JJ	overall	overall	overal	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
154	CD	154	154	154	N	O
(	(	(	(	(	N	O
40.7	CD	40.7	40.7	40.7	N	O
)	)	)	)	)	N	O
163	CD	163	163	163	N	O
(	(	(	(	(	N	O
43.2	CD	43.2	43.2	43.2	N	O
)	)	)	)	)	N	O

Severe	NNP	severe	severe	sever	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
13	CD	13	13	13	N	O
(	(	(	(	(	N	O
3.4	CD	3.4	3.4	3.4	N	O
)	)	)	)	)	N	O
15	CD	15	15	15	N	O
(	(	(	(	(	N	O
4.0	CD	4.0	4.0	4.0	N	O
)	)	)	)	)	N	O

In	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
with	IN	with	with	with	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
Pioglitazone	NNP	pioglitazone	pioglitazone	pioglitazon	N	O
(	(	(	(	(	N	O
26	CD	26	26	26	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
Pioglitazone	NNP	pioglitazone	pioglitazone	pioglitazon	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
115	CD	115	115	115	N	O
)	)	)	)	)	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
Pioglitazone	NNP	pioglitazone	pioglitazone	pioglitazon	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
113	CD	113	113	113	N	O
)	)	)	)	)	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
Metformin	NNP	metformin	metformin	metformin	N	O
Pioglitazone	NNP	pioglitazone	pioglitazone	pioglitazon	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
114	CD	114	114	114	N	O
)	)	)	)	)	N	O

Overall	JJ	overall	overall	overal	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
2.6	CD	2.6	2.6	2.6	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
2.7	CD	2.7	2.7	2.7	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

In	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
with	IN	with	with	with	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
(	(	(	(	(	N	O
18	CD	18	18	18	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
565	CD	565	565	565	N	O
)	)	)	)	)	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
566	CD	566	566	566	N	O
)	)	)	)	)	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
587	CD	587	587	587	N	O
)	)	)	)	)	N	O

Overall	JJ	overall	overall	overal	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
208	CD	208	208	208	N	O
(	(	(	(	(	N	O
36.8	CD	36.8	36.8	36.8	N	O
)	)	)	)	)	N	O
279	CD	279	279	279	N	O
(	(	(	(	(	N	O
49.3	CD	49.3	49.3	49.3	N	O
)	)	)	)	)	N	O
285	CD	285	285	285	N	O
(	(	(	(	(	N	O
48.6	CD	48.6	48.6	48.6	N	O
)	)	)	)	)	N	O

Severe	NNP	severe	severe	sever	N	O
[	NNP	[	[	[	N	O
N	NNP	n	n	n	N	O
(	(	(	(	(	N	O
)]	JJ	)]	)]	)]	N	O
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
2.5	CD	2.5	2.5	2.5	N	O
)	)	)	)	)	N	O
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
1.8	CD	1.8	1.8	1.8	N	O
)	)	)	)	)	N	O
16	CD	16	16	16	N	O
(	(	(	(	(	N	O
2.7	CD	2.7	2.7	2.7	N	O
)	)	)	)	)	N	O

Bone	CD	bone	bone	bone	N	O
Fracture	NN	fracture	fracture	fractur	Y	O

The	DT	the	the	the	N	O

occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
bone	NN	bone	bone	bone	N	B-AdverseReaction
fractures	NNS	fractures	fracture	fractur	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
nine	CD	nine	nine	nine	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
mean	JJ	mean	mean	mean	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
of	IN	of	of	of	N	O
85	CD	85	85	85	N	O
weeks	NNS	weeks	week	week	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
rates	NNS	rates	rate	rate	N	O
of	IN	of	of	of	N	O
adjudicated	JJ	adjudicated	adjudicated	adjud	N	O
bone	NN	bone	bone	bone	N	B-AdverseReaction
fractures	NNS	fractures	fracture	fractur	N	I-AdverseReaction
were	VBD	were	were	were	N	O
1.1	CD	1.1	1.1	1.1	N	O
,	,	,	,	,	N	O
1.4	CD	1.4	1.4	1.4	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
1.5	CD	1.5	1.5	1.5	N	O
per	IN	per	per	per	N	O
100	CD	100	100	100	N	O
patient	JJ	patient	patient	patient	N	O
-	:	-	-	-	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
comparator	NN	comparator	comparator	compar	N	O
,	,	,	,	,	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
groups	NNS	groups	group	group	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Fractures	NNS	fractures	fracture	fractur	N	B-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
as	RB	as	a	as	N	O
early	JJ	early	early	earli	N	O
as	IN	as	a	as	N	O
12	CD	12	12	12	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
initiation	NN	initiation	initiation	initi	N	O
and	CC	and	and	and	N	O
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
likely	JJ	likely	likely	like	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
low	JJ	low	low	low	N	B-Severity
trauma	NN	trauma	trauma	trauma	Y	I-Severity
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
fall	NN	fall	fall	fall	Y	O
from	IN	from	from	from	N	O
no	DT	no	no	no	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
standing	VBG	standing	standing	stand	N	O
height	NN	height	height	height	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
affect	VB	affect	affect	affect	N	O
the	DT	the	the	the	N	O
upper	JJ	upper	upper	upper	N	I-AdverseReaction
extremities	NNS	extremities	extremity	extrem	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O
and	CC	and	and	and	N	O
Imaging	NNP	imaging	imaging	imag	N	O
Tests	NNS	tests	test	test	N	O

Increases	NNS	increases	increase	increas	N	O
in	IN	in	in	in	N	O
Serum	NNP	serum	serum	serum	N	O
Potassium	NNP	potassium	potassium	potassium	Y	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
pooled	JJ	pooled	pooled	pool	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
723	CD	723	723	723	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
(	(	(	(	(	N	O
eGFR	JJ	egfr	egfr	egfr	N	O
45	CD	45	45	45	N	O
to	TO	to	to	to	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
60	CD	60	60	60	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
increases	VBZ	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	NN	serum	serum	serum	N	I-AdverseReaction
potassium	NN	potassium	potassium	potassium	Y	I-AdverseReaction
to	TO	to	to	to	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
5.4	CD	5.4	5.4	5.4	N	B-Severity
mEq	JJ	meq	meq	meq	N	I-Severity
L	NNP	l	l	l	N	I-Severity
and	CC	and	and	and	N	O
15%	CD	15%	15%	15%	N	B-Severity
above	IN	above	above	abov	N	I-Severity
baseline	NN	baseline	baseline	baselin	N	I-Severity
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
5.3%	CD	5.3%	5.3%	5.3%	N	O
,	,	,	,	,	N	O
5.0%	CD	5.0%	5.0%	5.0%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
8.8%	CD	8.8%	8.8%	8.8%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Severe	JJ	severe	severe	sever	N	O
elevations	NNS	elevations	elevation	elev	N	O
(	(	(	(	(	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
or	CC	or	or	or	N	O
equal	JJ	equal	equal	equal	N	O
to	TO	to	to	to	N	O
6.5	CD	6.5	6.5	6.5	N	O
mEq	NNS	meq	meq	meq	N	O
L	NNP	l	l	l	N	O
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
no	DT	no	no	no	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
potassium	NN	potassium	potassium	potassium	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
more	JJR	more	more	more	N	O
commonly	RB	commonly	commonly	commonli	N	O
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
with	IN	with	with	with	N	O
elevated	JJ	elevated	elevated	elev	N	O
potassium	NN	potassium	potassium	potassium	Y	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
.	.	.	.	.	N	O

Among	IN	among	among	among	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
,	,	,	,	,	N	O
approximately	RB	approximately	approximately	approxim	N	O
84%	CD	84%	84%	84%	N	O
were	VBD	were	were	were	N	O
taking	VBG	taking	taking	take	N	O
medications	NNS	medications	medication	medic	N	O
that	WDT	that	that	that	N	O
interfere	VBP	interfere	interfere	interfer	N	O
with	IN	with	with	with	N	O
potassium	NN	potassium	potassium	potassium	Y	O
excretion	NN	excretion	excretion	excret	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
potassium	NN	potassium	potassium	potassium	Y	O
-	:	-	-	-	N	O
sparing	NN	sparing	sparing	spare	N	O
diuretics	NNS	diuretics	diuretic	diuret	N	O
,	,	,	,	,	N	O
angiotensin	SYM	angiotensin	angiotensin	angiotensin	N	O
-	:	-	-	-	N	O
converting	VBG	converting	converting	convert	N	O
-	:	-	-	-	N	O
enzyme	NN	enzyme	enzyme	enzym	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
angiotensin	SYM	angiotensin	angiotensin	angiotensin	N	O
-	:	-	-	-	N	O
receptor	NN	receptor	receptor	receptor	N	O
blockers	NNS	blockers	blocker	blocker	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
and	CC	and	and	and	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.6	CD	8.6	8.6	8.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Increases	NNS	increases	increase	increas	N	O
in	IN	in	in	in	N	O
Serum	NNP	serum	serum	serum	N	O
Magnesium	NNP	magnesium	magnesium	magnesium	Y	O

Dose	NNP	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
magnesium	NN	magnesium	magnesium	magnesium	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
early	RB	early	early	earli	N	O
after	IN	after	after	after	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
(	(	(	(	(	N	O
within	IN	within	within	within	N	O
6	CD	6	6	6	N	O
weeks	NNS	weeks	week	week	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
remained	VBD	remained	remained	remain	N	O
elevated	VBN	elevated	elevated	elev	N	O
throughout	IN	throughout	throughout	throughout	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
four	CD	four	four	four	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
percent	NN	percent	percent	percent	N	O
change	NN	change	change	chang	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
magnesium	NN	magnesium	magnesium	magnesium	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
8.1%	CD	8.1%	8.1%	8.1%	N	O
and	CC	and	and	and	N	O
9.3%	CD	9.3%	9.3%	9.3%	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
-	:	-	-	-	N	O
0.6%	CD	0.6%	0.6%	0.6%	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.3	CD	14.3	14.3	14.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
,	,	,	,	,	N	O
serum	JJ	serum	serum	serum	N	B-AdverseReaction
magnesium	NN	magnesium	magnesium	magnesium	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
increased	VBN	increased	increased	increas	N	I-AdverseReaction
by	IN	by	by	by	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
,	,	,	,	,	N	O
9.2%	CD	9.2%	9.2%	9.2%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
14.8%	CD	14.8%	14.8%	14.8%	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Increases	NNS	increases	increase	increas	N	O
in	IN	in	in	in	N	O
Serum	NNP	serum	serum	serum	N	O
Phosphate	NNP	phosphate	phosphate	phosphat	Y	O

Dose	NNP	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
phosphate	NN	phosphate	phosphate	phosphat	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
four	CD	four	four	four	N	O
placebo	NN	placebo	placebo	placebo	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
percent	NN	percent	percent	percent	N	O
change	NN	change	change	chang	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
phosphate	NN	phosphate	phosphate	phosphat	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
were	VBD	were	were	were	N	O
3.6%	CD	3.6%	3.6%	3.6%	N	O
and	CC	and	and	and	N	O
5.1%	CD	5.1%	5.1%	5.1%	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.3	CD	14.3	14.3	14.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
serum	NN	serum	serum	serum	N	B-AdverseReaction
phosphate	NN	phosphate	phosphate	phosphat	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
increased	VBN	increased	increased	increas	N	I-AdverseReaction
by	IN	by	by	by	N	O
1.2%	CD	1.2%	1.2%	1.2%	N	O
,	,	,	,	,	N	O
5.0%	CD	5.0%	5.0%	5.0%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
9.3%	CD	9.3%	9.3%	9.3%	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Increases	NNS	increases	increase	increas	N	O
in	IN	in	in	in	N	O
Low	NNP	low	low	low	N	O
-	:	-	-	-	N	O
Density	NN	density	density	densiti	N	O
Lipoprotein	NNP	lipoprotein	lipoprotein	lipoprotein	N	O
Cholesterol	NNP	cholesterol	cholesterol	cholesterol	Y	O
(	(	(	(	(	N	O
LDL	NNP	ldl	ldl	ldl	Y	O
-	:	-	-	-	N	O
C	NNP	c	c	c	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
non	$	non	non	non	N	O
-	:	-	-	-	N	O
High	NNP	high	high	high	N	O
-	:	-	-	-	N	O
Density	NNP	density	density	densiti	N	O
Lipoprotein	NNP	lipoprotein	lipoprotein	lipoprotein	N	O
Cholesterol	NNP	cholesterol	cholesterol	cholesterol	Y	O
(	(	(	(	(	N	O
non	SYM	non	non	non	N	O
-	:	-	-	-	N	O
HDL	NNP	hdl	hdl	hdl	Y	O
-	:	-	-	-	N	O
C	NN	c	c	c	N	O
)	)	)	)	)	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
four	CD	four	four	four	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
dose	SYM	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
LDL	NNP	ldl	ldl	ldl	Y	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
C	NN	c	c	c	N	I-AdverseReaction
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
.	.	.	.	.	N	O

Mean	JJ	mean	mean	mean	N	O
changes	NNS	changes	change	chang	N	B-AdverseReaction
(	(	(	(	(	N	O
percent	NN	percent	percent	percent	N	O
changes	NNS	changes	change	chang	N	O
)	)	)	)	)	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	I-AdverseReaction
LDL	NNP	ldl	ldl	ldl	Y	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
relative	VBP	relative	relative	rel	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
were	VBD	were	were	were	N	O
4.4	CD	4.4	4.4	4.4	N	B-Severity
mg	NNS	mg	mg	mg	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
(	(	(	(	(	N	O
4.5%	CD	4.5%	4.5%	4.5%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
8.2	CD	8.2	8.2	8.2	N	B-Severity
mg	NN	mg	mg	mg	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
(	(	(	(	(	N	O
8.0%	CD	8.0%	8.0%	8.0%	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
baseline	NN	baseline	baseline	baselin	N	O
LDL	NNP	ldl	ldl	ldl	Y	O
-	:	-	-	-	N	O
C	NN	c	c	c	N	O
levels	NNS	levels	level	level	N	O
were	VBD	were	were	were	N	O
104	CD	104	104	104	N	O
to	TO	to	to	to	N	O
110	CD	110	110	110	N	O
mg	NNS	mg	mg	mg	N	O
dL	JJ	dl	dl	dl	N	O
across	IN	across	across	across	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Dose	NNP	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
non	JJ	non	non	non	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
HDL	NNP	hdl	hdl	hdl	Y	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
C	NN	c	c	c	N	I-AdverseReaction
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
.	.	.	.	.	N	O

Mean	JJ	mean	mean	mean	N	O
changes	NNS	changes	change	chang	N	B-AdverseReaction
(	(	(	(	(	N	O
percent	NN	percent	percent	percent	N	O
changes	NNS	changes	change	chang	N	O
)	)	)	)	)	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	I-AdverseReaction
non	JJ	non	non	non	N	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
HDL	NNP	hdl	hdl	hdl	Y	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
relative	VBP	relative	relative	rel	N	O
to	TO	to	to	to	N	O
placebo	VB	placebo	placebo	placebo	N	O
were	VBD	were	were	were	N	O
2.1	CD	2.1	2.1	2.1	N	B-Severity
mg	NNS	mg	mg	mg	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
(	(	(	(	(	N	O
1.5%	CD	1.5%	1.5%	1.5%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
5.1	CD	5.1	5.1	5.1	N	B-Severity
mg	NN	mg	mg	mg	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
(	(	(	(	(	N	O
3.6%	CD	3.6%	3.6%	3.6%	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
baseline	NN	baseline	baseline	baselin	N	O
non	SYM	non	non	non	N	O
-	:	-	-	-	N	O
HDL	NNP	hdl	hdl	hdl	Y	O
-	:	-	-	-	N	O
C	NN	c	c	c	N	O
levels	NNS	levels	level	level	N	O
were	VBD	were	were	were	N	O
140	CD	140	140	140	N	O
to	TO	to	to	to	N	O
147	CD	147	147	147	N	O
mg	NNS	mg	mg	mg	N	O
dL	JJ	dl	dl	dl	N	O
across	IN	across	across	across	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
.	.	.	.	.	N	O

Increases	NNS	increases	increase	increas	N	O
in	IN	in	in	in	N	O
Hemoglobin	NNP	hemoglobin	hemoglobin	hemoglobin	Y	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
pool	NN	pool	pool	pool	N	O
of	IN	of	of	of	N	O
four	CD	four	four	four	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
mean	JJ	mean	mean	mean	N	O
changes	NNS	changes	change	chang	N	B-AdverseReaction
(	(	(	(	(	N	O
percent	NN	percent	percent	percent	N	O
changes	NNS	changes	change	chang	N	O
)	)	)	)	)	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
in	IN	in	in	in	N	I-AdverseReaction
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
-	:	-	-	-	N	O
0.18	CD	0.18	0.18	0.18	N	O
g	JJ	g	g	g	N	O
dL	JJ	dl	dl	dl	N	O
(-	JJ	(-	(-	(-	N	O
1.1%	CD	1.1%	1.1%	1.1%	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
0.47	CD	0.47	0.47	0.47	N	B-Severity
g	NN	g	g	g	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
(	(	(	(	(	N	O
3.5%	CD	3.5%	3.5%	3.5%	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
0.51	CD	0.51	0.51	0.51	N	B-Severity
g	NN	g	g	g	N	I-Severity
dL	NN	dl	dl	dl	N	I-Severity
(	(	(	(	(	N	O
3.8%	CD	3.8%	3.8%	3.8%	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
baseline	NN	baseline	baseline	baselin	N	O
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	O
value	NN	value	value	valu	N	O
was	VBD	was	wa	wa	N	O
approximately	RB	approximately	approximately	approxim	N	O
14.1	CD	14.1	14.1	14.1	N	O
g	NNS	g	g	g	N	O
dL	JJ	dl	dl	dl	N	O
across	IN	across	across	across	N	O
treatment	NN	treatment	treatment	treatment	N	O
groups	NNS	groups	group	group	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
the	DT	the	the	the	N	O
end	NN	end	end	end	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
0.8%	CD	0.8%	0.8%	0.8%	N	O
,	,	,	,	,	N	O
4.0%	CD	4.0%	4.0%	4.0%	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
2.7%	CD	2.7%	2.7%	2.7%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
,	,	,	,	,	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
had	VBD	had	had	had	N	O
hemoglobin	VBN	hemoglobin	hemoglobin	hemoglobin	Y	B-AdverseReaction
above	IN	above	above	abov	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
upper	JJ	upper	upper	upper	N	I-AdverseReaction
limit	NN	limit	limit	limit	N	I-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
normal	JJ	normal	normal	normal	N	I-AdverseReaction
.	.	.	.	.	N	O

Decreases	NNS	decreases	decrease	decreas	N	O
in	IN	in	in	in	N	O
Bone	NNP	bone	bone	bone	N	O
Mineral	NNP	mineral	mineral	miner	N	O
Density	NNP	density	density	densiti	N	O

Bone	NNP	bone	bone	bone	N	O
mineral	JJ	mineral	mineral	miner	N	O
density	NN	density	density	densiti	N	O
(	(	(	(	(	N	O
BMD	NNP	bmd	bmd	bmd	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
measured	VBN	measured	measured	measur	N	O
by	IN	by	by	by	N	O
dual	JJ	dual	dual	dual	N	O
-	:	-	-	-	N	O
energy	NN	energy	energy	energi	N	O
X	NNP	x	x	x	N	O
-	:	-	-	-	N	O
ray	NN	ray	ray	ray	N	O
absorptiometry	NN	absorptiometry	absorptiometry	absorptiometri	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
of	IN	of	of	of	N	O
714	CD	714	714	714	N	O
older	JJR	older	older	older	N	O
adults	NNS	adults	adult	adult	N	O
(	(	(	(	(	N	O
mean	JJ	mean	mean	mean	N	O
age	NN	age	age	age	N	O
64	CD	64	64	64	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14.3	CD	14.3	14.3	14.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

At	IN	at	at	at	N	O
2	CD	2	2	2	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBD	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
and	CC	and	and	and	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
had	VBD	had	had	had	N	O
placebo	VBN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
corrected	VBN	corrected	corrected	correct	N	O
declines	NNS	declines	decline	declin	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
BMD	NNP	bmd	bmd	bmd	N	I-AdverseReaction
at	IN	at	at	at	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
total	JJ	total	total	total	N	I-AdverseReaction
hip	NN	hip	hip	hip	N	I-AdverseReaction
of	IN	of	of	of	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	B-Severity
and	CC	and	and	and	N	O
1.2%	CD	1.2%	1.2%	1.2%	N	B-Severity
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
at	IN	at	at	at	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
lumbar	NN	lumbar	lumbar	lumbar	N	I-AdverseReaction
spine	NN	spine	spine	spine	N	I-AdverseReaction
of	IN	of	of	of	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	B-Severity
and	CC	and	and	and	N	O
0.7%	CD	0.7%	0.7%	0.7%	N	B-Severity
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Additionally	RB	additionally	additionally	addit	N	O
,	,	,	,	,	N	O
placebo	SYM	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
adjusted	VBN	adjusted	adjusted	adjust	N	O
BMD	NNP	bmd	bmd	bmd	N	B-AdverseReaction
declines	NNS	declines	decline	declin	N	I-AdverseReaction
were	VBD	were	were	were	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	B-Severity
at	IN	at	at	at	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
femoral	JJ	femoral	femoral	femor	N	I-AdverseReaction
neck	NN	neck	neck	neck	N	I-AdverseReaction
for	IN	for	for	for	N	O
both	DT	both	both	both	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
doses	NNS	doses	dos	dose	N	O
and	CC	and	and	and	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	B-Severity
at	IN	at	at	at	N	I-AdverseReaction
the	DT	the	the	the	N	I-AdverseReaction
distal	JJ	distal	distal	distal	N	I-AdverseReaction
forearm	NN	forearm	forearm	forearm	N	I-AdverseReaction
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
300	CD	300	300	300	N	O
mg	NN	mg	mg	mg	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
adjusted	VBN	adjusted	adjusted	adjust	N	O
change	NN	change	change	chang	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
distal	JJ	distal	distal	distal	N	O
forearm	NN	forearm	forearm	forearm	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
randomized	VBN	randomized	randomized	random	N	O
to	TO	to	to	to	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
100	CD	100	100	100	N	O
mg	NN	mg	mg	mg	N	O
was	VBD	was	wa	wa	N	O
0%	CD	0%	0%	0%	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
:	:	:	:	:	N	O
Before	IN	before	before	befor	N	O
initiating	VBG	initiating	initiating	initi	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
,	,	,	,	,	N	O
assess	NN	assess	ass	assess	N	O
volume	NN	volume	volume	volum	N	O
status	NN	status	status	statu	N	O
and	CC	and	and	and	N	O
correct	VB	correct	correct	correct	N	O
hypovolemia	NN	hypovolemia	hypovolemia	hypovolemia	Y	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
elderly	JJ	elderly	elderly	elderli	Y	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
low	JJ	low	low	low	N	O
systolic	JJ	systolic	systolic	systol	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
if	IN	if	if	if	N	O
on	IN	on	on	on	N	O
diuretics	NNS	diuretics	diuretic	diuret	N	O
,	,	,	,	,	N	O
ACEi	NNP	acei	acei	acei	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
ARB	NNP	arb	arb	arb	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Impairment	NN	impairment	impairment	impair	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
Renal	JJ	renal	renal	renal	N	I-AdverseReaction
Function	NN	function	function	function	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

More	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
eGFR	JJ	egfr	egfr	egfr	N	O
below	IN	below	below	below	N	O
60	CD	60	60	60	N	O
mL	NNS	ml	ml	ml	N	O
min	RB	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NNS	m	m	m	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Hyperkalemia	NN	hyperkalemia	hyperkalemia	hyperkalemia	Y	B-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
potassium	NN	potassium	potassium	potassium	Y	O
levels	NNS	levels	level	level	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
impaired	JJ	impaired	impaired	impair	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
predisposed	VBN	predisposed	predisposed	predispos	N	O
to	TO	to	to	to	N	O
hyperkalemia	VB	hyperkalemia	hyperkalemia	hyperkalemia	Y	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
,	,	,	,	,	N	O
5.3	CD	5.3	5.3	5.3	N	O
,	,	,	,	,	N	O
6.1	CD	6.1	6.1	6.1	N	O
,	,	,	,	,	N	O
8.6	CD	8.6	8.6	8.6	N	O
)	)	)	)	)	N	O

Hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
:	:	:	:	:	N	O
Consider	VB	consider	consider	consid	N	O
a	DT	a	a	a	N	O
lower	JJR	lower	lower	lower	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
insulin	NN	insulin	insulin	insulin	Y	O
or	CC	or	or	or	N	O
the	DT	the	the	the	N	O
insulin	NN	insulin	insulin	insulin	Y	O
secretagogue	NN	secretagogue	secretagogue	secretagogu	N	O
to	TO	to	to	to	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
when	WRB	when	when	when	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Genital	NNP	genital	genital	genit	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
if	IN	if	if	if	N	O
indicated	VBN	indicated	indicated	indic	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
:	:	:	:	:	N	O
Discontinue	NNP	discontinue	discontinue	discontinu	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
and	CC	and	and	and	N	O
monitor	NN	monitor	monitor	monitor	N	O
until	IN	until	until	until	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
resolve	VBP	resolve	resolve	resolv	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Bone	JJ	bone	bone	bone	N	B-AdverseReaction
fracture	NN	fracture	fracture	fractur	Y	I-AdverseReaction
:	:	:	:	:	N	O
Consider	VB	consider	consider	consid	N	O
factors	NNS	factors	factor	factor	N	O
that	WDT	that	that	that	N	O
contribute	VBP	contribute	contribute	contribut	N	O
to	TO	to	to	to	N	O
fracture	VB	fracture	fracture	fractur	Y	O
risk	NN	risk	risk	risk	N	O
before	IN	before	before	befor	N	O
initiating	VBG	initiating	initiating	initi	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

Increased	VBN	increased	increased	increas	N	B-AdverseReaction
LDL	NNP	ldl	ldl	ldl	Y	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
C	NN	c	c	c	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
LDL	NNP	ldl	ldl	ldl	Y	O
-	:	-	-	-	N	O
C	NNP	c	c	c	N	O
and	CC	and	and	and	N	O
treat	VB	treat	treat	treat	N	O
if	IN	if	if	if	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Hypotension	NN	hypotension	hypotension	hypotens	Y	O

INVOKANA	NN	invokana	invokana	invokana	N	O

causes	NNS	causes	cause	caus	N	O
intravascular	JJ	intravascular	intravascular	intravascular	N	B-AdverseReaction
volume	NN	volume	volume	volum	N	I-AdverseReaction
contraction	NN	contraction	contraction	contract	N	I-AdverseReaction
.	.	.	.	.	N	O

Symptomatic	JJ	symptomatic	symptomatic	symptomat	N	B-AdverseReaction
hypotension	NN	hypotension	hypotension	hypotens	Y	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
after	IN	after	after	after	N	O
initiating	VBG	initiating	initiating	initi	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	RB	)]	)]	)]	N	O
particularly	RB	particularly	particularly	particularli	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
impaired	JJ	impaired	impaired	impair	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
(	(	(	(	(	N	O
eGFR	RB	egfr	egfr	egfr	N	O
less	JJR	less	le	less	N	O
than	IN	than	than	than	N	O
60	CD	60	60	60	N	O
mL	JJ	ml	ml	ml	N	O
min	NN	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
elderly	JJ	elderly	elderly	elderli	Y	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
either	DT	either	either	either	N	O
diuretics	NNS	diuretics	diuretic	diuret	N	O
or	CC	or	or	or	N	O
medications	NNS	medications	medication	medic	N	O
that	WDT	that	that	that	N	O
interfere	VBP	interfere	interfere	interfer	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
renin	NN	renin	renin	renin	Y	O
-	:	-	-	-	N	O
angiotensin	NN	angiotensin	angiotensin	angiotensin	N	O
-	:	-	-	-	N	O
aldosterone	NN	aldosterone	aldosterone	aldosteron	Y	O
system	NN	system	system	system	N	O
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
angiotensin	SYM	angiotensin	angiotensin	angiotensin	N	O
-	:	-	-	-	N	O
converting	VBG	converting	converting	convert	N	O
-	:	-	-	-	N	O
enzyme	NN	enzyme	enzyme	enzym	N	O
[	JJ	[	[	[	N	O
ACE	NNP	ace	ace	ace	N	O
]	NNP	]	]	]	N	O
inhibitors	NNS	inhibitors	inhibitor	inhibitor	N	O
,	,	,	,	,	N	O
angiotensin	NN	angiotensin	angiotensin	angiotensin	N	O
receptor	NN	receptor	receptor	receptor	N	O
blockers	NNS	blockers	blocker	blocker	N	O
[	VBP	[	[	[	N	O
ARBs	NNP	arbs	arb	arb	N	O
])	NNP	])	])	])	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
low	JJ	low	low	low	N	O
systolic	JJ	systolic	systolic	systol	N	O
blood	NN	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
.	.	.	.	.	N	O

Before	IN	before	before	befor	N	O
initiating	VBG	initiating	initiating	initi	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
one	CD	one	one	one	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
characteristics	NNS	characteristics	characteristic	characterist	N	O
,	,	,	,	,	N	O
volume	NN	volume	volume	volum	N	O
status	NN	status	status	statu	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
assessed	VBN	assessed	assessed	assess	N	O
and	CC	and	and	and	N	O
corrected	VBN	corrected	corrected	correct	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
after	IN	after	after	after	N	O
initiating	VBG	initiating	initiating	initi	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Impairment	NNP	impairment	impairment	impair	N	O
in	IN	in	in	in	N	O
Renal	NNP	renal	renal	renal	N	O
Function	NNP	function	function	function	N	O

INVOKANA	NNP	invokana	invokana	invokana	N	O
increases	VBZ	increases	increase	increas	N	B-AdverseReaction
serum	JJ	serum	serum	serum	N	I-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
and	CC	and	and	and	N	O
decreases	VBZ	decreases	decrease	decreas	N	B-AdverseReaction
eGFR	NN	egfr	egfr	egfr	N	I-AdverseReaction
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
hypovolemia	NN	hypovolemia	hypovolemia	hypovolemia	Y	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
more	RBR	more	more	more	N	O
susceptible	JJ	susceptible	susceptible	suscept	N	O
to	TO	to	to	to	N	O
these	DT	these	these	these	N	O
changes	NNS	changes	change	chang	N	O
.	.	.	.	.	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
function	NN	function	function	function	N	I-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
after	IN	after	after	after	N	O
initiating	VBG	initiating	initiating	initi	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

More	RBR	more	more	more	N	O
frequent	JJ	frequent	frequent	frequent	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
an	DT	an	an	an	N	O
eGFR	NN	egfr	egfr	egfr	N	O
below	IN	below	below	below	N	O
60	CD	60	60	60	N	O
mL	NNS	ml	ml	ml	N	O
min	RB	min	min	min	N	O
1.73	CD	1.73	1.73	1.73	N	O
m	JJ	m	m	m	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Hyperkalemia	NN	hyperkalemia	hyperkalemia	hyperkalemia	Y	O

INVOKANA	NNP	invokana	invokana	invokana	N	O
can	MD	can	can	can	N	B-Factor
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
hyperkalemia	VB	hyperkalemia	hyperkalemia	hyperkalemia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
renal	JJ	renal	renal	renal	N	O
impairment	NN	impairment	impairment	impair	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
taking	VBG	taking	taking	take	N	O
medications	NNS	medications	medication	medic	N	O
that	WDT	that	that	that	N	O
interfere	VBP	interfere	interfere	interfer	N	O
with	IN	with	with	with	N	O
potassium	NN	potassium	potassium	potassium	Y	O
excretion	NN	excretion	excretion	excret	N	O
,	,	,	,	,	N	O
such	JJ	such	such	such	N	O
as	IN	as	a	as	N	O
potassium	NN	potassium	potassium	potassium	Y	O
-	:	-	-	-	N	O
sparing	NN	sparing	sparing	spare	N	O
diuretics	NNS	diuretics	diuretic	diuret	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
medications	NNS	medications	medication	medic	N	O
that	WDT	that	that	that	N	O
interfere	VBP	interfere	interfere	interfer	N	O
with	IN	with	with	with	N	O
the	DT	the	the	the	N	O
renin	NN	renin	renin	renin	Y	O
-	:	-	-	-	N	O
angiotensin	NN	angiotensin	angiotensin	angiotensin	N	O
-	:	-	-	-	N	O
aldosterone	NN	aldosterone	aldosterone	aldosteron	Y	O
system	NN	system	system	system	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
developing	VBG	developing	developing	develop	N	O
hyperkalemia	JJ	hyperkalemia	hyperkalemia	hyperkalemia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
serum	VBD	serum	serum	serum	N	O
potassium	NN	potassium	potassium	potassium	Y	O
levels	NNS	levels	level	level	N	O
periodically	RB	periodically	periodically	period	N	O
after	IN	after	after	after	N	O
initiating	VBG	initiating	initiating	initi	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
impaired	JJ	impaired	impaired	impair	N	O
renal	JJ	renal	renal	renal	N	O
function	NN	function	function	function	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
predisposed	VBN	predisposed	predisposed	predispos	N	O
to	TO	to	to	to	N	O
hyperkalemia	VB	hyperkalemia	hyperkalemia	hyperkalemia	Y	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
medications	NNS	medications	medication	medic	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
medical	JJ	medical	medical	medic	N	O
conditions	NNS	conditions	condition	condit	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Hypoglycemia	NNP	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
with	IN	with	with	with	N	O
Concomitant	NNP	concomitant	concomitant	concomit	N	O
Use	NNP	use	use	use	N	O
with	IN	with	with	with	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
and	CC	and	and	and	N	O
Insulin	NNP	insulin	insulin	insulin	Y	O
Secretagogues	NNP	secretagogues	secretagogues	secretagogu	N	O

Insulin	NNP	insulin	insulin	insulin	Y	O
and	CC	and	and	and	N	O
insulin	NN	insulin	insulin	insulin	Y	O
secretagogues	NNS	secretagogues	secretagogues	secretagogu	N	O
are	VBP	are	are	are	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
cause	VB	cause	cause	caus	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
.	.	.	.	.	N	O

INVOKANA	NNP	invokana	invokana	invokana	N	O
can	MD	can	can	can	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
when	WRB	when	when	when	N	O
combined	VBN	combined	combined	combin	N	O
with	IN	with	with	with	N	O
insulin	NN	insulin	insulin	insulin	Y	O
or	CC	or	or	or	N	O
an	DT	an	an	an	N	O
insulin	JJ	insulin	insulin	insulin	Y	O
secretagogue	NN	secretagogue	secretagogue	secretagogu	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
lower	JJR	lower	lower	lower	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
insulin	NN	insulin	insulin	insulin	Y	O
or	CC	or	or	or	N	O
insulin	NN	insulin	insulin	insulin	Y	O
secretagogue	NN	secretagogue	secretagogue	secretagogu	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
required	VBN	required	required	requir	N	O
to	TO	to	to	to	N	O
minimize	VB	minimize	minimize	minim	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
hypoglycemia	NN	hypoglycemia	hypoglycemia	hypoglycemia	Y	O
when	WRB	when	when	when	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Genital	NNP	genital	genital	genit	N	O
Mycotic	NNP	mycotic	mycotic	mycot	N	O
Infections	NNP	infections	infection	infect	N	O

INVOKANA	NNP	invokana	invokana	invokana	N	O
increases	VBZ	increases	increase	increas	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
genital	JJ	genital	genital	genit	N	O
mycotic	JJ	mycotic	mycotic	mycot	N	O
infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
uncircumcised	JJ	uncircumcised	uncircumcised	uncircumcis	Y	O
males	NNS	males	male	male	N	O
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
likely	JJ	likely	likely	like	N	O
to	TO	to	to	to	N	O
develop	VB	develop	develop	develop	N	O
genital	JJ	genital	genital	genit	N	B-AdverseReaction
mycotic	JJ	mycotic	mycotic	mycot	N	I-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VB	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
appropriately	RB	appropriately	appropriately	appropri	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
(	(	(	(	(	N	O
e	NN	e	e	e	N	O
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
.	.	.	.	.	N	O
,	,	,	,	,	N	O
generalized	JJ	generalized	generalized	gener	N	B-AdverseReaction
urticaria	NN	urticaria	urticaria	urticaria	Y	I-AdverseReaction
)	)	)	)	)	N	O
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
serious	JJ	serious	serious	seriou	N	B-Severity
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
treatment	NN	treatment	treatment	treatment	N	O
;	:	;	;	;	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
generally	RB	generally	generally	gener	N	O
occurred	VBD	occurred	occurred	occur	N	O
within	IN	within	within	within	N	O
hours	NNS	hours	hour	hour	N	O
to	TO	to	to	to	N	O
days	NNS	days	day	day	N	O
after	IN	after	after	after	N	O
initiating	VBG	initiating	initiating	initi	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
occur	VBP	occur	occur	occur	N	O
,	,	,	,	,	N	O
discontinue	VBP	discontinue	discontinue	discontinu	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
;	:	;	;	;	N	O
treat	NN	treat	treat	treat	N	O
and	CC	and	and	and	N	O
monitor	NN	monitor	monitor	monitor	N	O
until	IN	until	until	until	N	O
signs	NNS	signs	sign	sign	N	O
and	CC	and	and	and	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
resolve	VBP	resolve	resolve	resolv	N	O
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Bone	CD	bone	bone	bone	N	O
Fracture	NN	fracture	fracture	fractur	Y	O

An	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
bone	NN	bone	bone	bone	N	B-AdverseReaction
fracture	NN	fracture	fracture	fractur	Y	I-AdverseReaction
,	,	,	,	,	N	O
occurring	VBG	occurring	occurring	occur	N	O
as	RB	as	a	as	N	O
early	RB	early	early	earli	N	O
as	IN	as	a	as	N	O
12	CD	12	12	12	N	O
weeks	NNS	weeks	week	week	N	O
after	IN	after	after	after	N	O
treatment	NN	treatment	treatment	treatment	N	O
initiation	NN	initiation	initiation	initi	N	O
,	,	,	,	,	N	O
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
using	VBG	using	using	use	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
factors	NNS	factors	factor	factor	N	O
that	WDT	that	that	that	N	O
contribute	VBP	contribute	contribute	contribut	N	O
to	TO	to	to	to	N	O
fracture	VB	fracture	fracture	fractur	Y	O
risk	NN	risk	risk	risk	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Increases	NNS	increases	increase	increas	N	O
in	IN	in	in	in	N	O
Low	NNP	low	low	low	N	O
-	:	-	-	-	N	O
Density	NN	density	density	densiti	N	O
Lipoprotein	NNP	lipoprotein	lipoprotein	lipoprotein	N	O
(	(	(	(	(	N	O
LDL	NNP	ldl	ldl	ldl	Y	O
-	:	-	-	-	N	O
C	NN	c	c	c	N	O
)	)	)	)	)	N	O

Dose	NNP	dose	dose	dose	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
LDL	NNP	ldl	ldl	ldl	Y	I-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
C	NNP	c	c	c	N	I-AdverseReaction
occur	VBP	occur	occur	occur	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
LDL	NNP	ldl	ldl	ldl	Y	O
-	:	-	-	-	N	O
C	NNP	c	c	c	N	O
and	CC	and	and	and	N	O
treat	VB	treat	treat	treat	N	O
if	IN	if	if	if	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
after	IN	after	after	after	N	O
initiating	VBG	initiating	initiating	initi	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
Macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
Outcomes	NNS	outcomes	outcome	outcom	N	O

There	EX	there	there	there	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
no	DT	no	no	no	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
establishing	VBG	establishing	establishing	establish	N	O
conclusive	JJ	conclusive	conclusive	conclus	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
macrovascular	JJ	macrovascular	macrovascular	macrovascular	N	O
risk	NN	risk	risk	risk	N	O
reduction	NN	reduction	reduction	reduct	N	O
with	IN	with	with	with	N	O
INVOKANA	NNP	invokana	invokana	invokana	N	O
or	CC	or	or	or	N	O
any	DT	any	any	ani	N	O
other	JJ	other	other	other	N	O
antidiabetic	JJ	antidiabetic	antidiabetic	antidiabet	N	O
drug	NN	drug	drug	drug	N	O
.	.	.	.	.	N	O

